1. Hof H. A new, broad-spectrum azole antifungal: posaconazole–mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49(Suppl 1):2–6. https://doi.org/10.1111/j.1439-0507.2006.01295.x.
2. U.S FDA. Noxafil instruction. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205053s1lbl.pdf. Accessed 15 Apr 2020.
3. European Medicines Agency. Summary of posaconazole characteristics. 2010. https://www.ema.europa.eu/en/documents/product-information/noxafil-epar-product-information_en.pdf. Accessed 15 Apr 2020.
4. The European Committee on Antimicrobial Susceptibility Testing. Posaconazole: Rationale for the EUCAST clinical breakpoints, version 2.0. 2017. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/Posaconazole_Yeast_Molds_RD_V.2_Apr__2017.pdf. Accessed 15 Apr 2020.
5. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004;48(1):137–42.